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Abstract Previous evidence supports a role for growth
hormone (GH)–insulin-like growth factor (IGF)-I defi-
ciency in the pathophysiology of osteopenia/osteoporosis
in adult thalassemia. Moreover, serum IGF-II has never
been studied in this clinical condition. Thus, we elected to
study the GH secretory status and the levels of circulating
somatomedins, correlating these parameters with bone
mineral density (BMD) and biochemical markers of bone
turnover. A hundred and thirty-nine normal weight adult
thalassemic patients (72 men and 67 women) were studied.
Lumbar and femoral neck BMD were measured in 106/139
patients. Sixty-eight patients underwent growth hormone
releasing hormone plus arginine testing. Measurement of
baseline IGF-I and IGF-II was performed in all patients,
while osteocalcin, C-terminal telopeptide of type I collagen
(CTx), and urinary cross-linked N-telopeptides of type I
collagen (NTx) were assayed in 95 of them. Femoral and
lumbar osteoporosis/Z score below the expected range for
age were documented in 61.3 and in 56.6 % of patients,
respectively. Severe GH deficiency (GHD) was demon-
strated in 27.9 % of cases, whereas IGF-I SDS was low in
86.3 %. No thalassemic patients displayed circulating
levels of IGF-II below the reference range. GH peaks were
positively correlated with femoral, but not lumbar, Z score.
No correlations were found between GH peaks and
osteocalcin, CTx and NTx. GH peaks were positively
correlated with IGF-I values, which in their turn displayed
a positive correlation with osteocalcin, CTx, and NTx. No
correlations emerged between IGF-I values and either
femoral or lumbar Z scores. No correlations were found
between IGF-II and any of the following parameters: GH
peaks, osteocalcin, CTx, NTx, femoral Z score, and lumbar
Z score. Our study, besides providing for the first time
evidence of a normal IGF-II production in thalassemia,
contributes to a better understanding of the involvement of
the somatotropin-somatomedin axis in the pathophysiology
of bone demineralization in this disease. In particular, the
contribution of GHD to femoral osteoporosis appears to be
likely mediated by locally produced rather than circulating
IGF-I.
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Introduction
Among the systemic comorbidities affecting adult tha-
lassemic patients, bone demineralization is extremely fre-
quent [1]. Genetic, hematological, iatrogenic, and endocrine
factors are thought to contribute to this complication [2–5].
Previous data from our group suggested a role for growth
hormone (GH)–insulin-like growth factor (IGF)-I defi-
ciency in the pathophysiology of osteopenia/osteoporosis in
thalassemia, in particular at the femoral level [1].
In vitro, both IGF-I and IGF-II are known to stimulate
human osteoblast proliferation, differentiation, and colla-
gen synthesis via IGF-I receptor [6]. Recent in vivo find-
ings point to IGF-II decrease as a major contributor to the
reduced calcaneal bone mineral density (BMD) observed in
elderly women [7]. Serum levels of IGF-II have never been
determined in patients with b-thalassemia.
Based on these considerations, we elected to further
investigate, in a large series of thalassemic adults, the GH
secretory status and the levels of circulating somatomedins,
correlating these parameters with BMD and biochemical
markers of bone turnover.
Patients and methods
Patients
A total of 139 adult thalassemic patients (72 men and 67
women), aged 32.3 ± 7.87 years (range 28–58), were
studied. Mean height of the patients was 159.2 ± 10.21 cm,
their mean height SDS was -1.06 ± 1.55, and mean body
mass index (BMI) was 21.3 ± 3.04 kg/m2. One hundred
and thirty-two of them were affected by b-thalassemia
major and 7 by b-thalassemia intermedia. All Cooley’s
patients were on stable transfusion regimen. At the time of
the study, hemoglobin levels were[7.5 g/dl. All subjects,
with the exception of the 7 patients with thalassemia
intermedia, were receiving adequate iron chelation, i.e.,
infusions of desferrioxamine (Desferal, Novartis, Origgio,
Italy) 30–50 mg/kg body weight 5 days a week or oral
deferasirox (Exjade, Novartis, Origgio, Italy) 20–30 mg/kg
body weight daily. Fifty-six of them had undergone
splenectomy in childhood. None of the patients had been
investigated for GH secretion and had received GH
replacement therapy during childhood.
Twenty-four male and thirty-eight female subjects were
affected by hypogonadotropic hypogonadism and were on
sex steroid replacement therapy [testosterone enanthate
(Testo Enant, Geymonat SpA, Anagni, Italy) at the mean
dose of 250 mg i.m. monthly in men and standard estro-
gen-progestogen association in women]. Primary
hypothyroidism was present in 4 patients, who were
receiving 50–175 lg daily levothyroxine (Eutirox, Bracco
SpA, Milan, Italy). None of the patients had been diag-
nosed with adrenal insufficiency. Sixteen patients had
impaired glucose tolerance and were following a proper
diet regimen. Thirty-eight patients were affected by hep-
atitis C virus-related chronic liver disease: 26 of them had
been previously treated with interferon while, at the
moment of the study, no patient was on such treatment; all
patients displayed normal or slightly elevated transaminase
values and none of them had severe liver disease. Finally,
10 patients had experienced clinical fractures but none of
the subjects, at the moment of the evaluation, was receiving
bisphosphonate therapy or vitamin D-calcium supplemen-
tation; unfortunately no data on morphometric fractures
were available for this series.
All patients gave their informed consent to participate in
the study, which was approved by the Ethics Committee of
our Institution.
Measurement of BMD
BMD was assessed by dual energy X-ray absorptiometry
(DEXA) using a Hologic QDR 2000 Plus densitometer
(Hologic Italia srl, Rome, Italy). Both lumbar (L1–L4) and
femoral neck BMD were measured in 106 (55 men and 51
women) out of 139 patients. In agreement with the 2015
official position of the International Society for Clinical
Densitometry, in patients aged 50 years or older (only 5 out
the 106 undergone DEXA) osteoporosis was defined by a
T score lower than -2.5, while in the vast majority of the
patients, the so-called condition of BMD below the expected
range for age was defined by a Z score lower than -2.0.
Test procedures
In a subset of 68 patients (36 men and 32 women), GH was
measured before and after stimulation with growth hor-
mone releasing hormone (GHRH) plus arginine. An
indwelling catheter was placed into a forearm vein between
7.00 and 8.00 AM and kept patent by saline infusion. Two
baseline samples were collected at least 15-min apart prior
to the injection of 1 lg/kg body weight GHRH (Ferring
SpA, Milan, Italy) as an i.v. bolus and the infusion of 0.5 g/
kg body weight (maximal dose 30 g) arginine (S.A.L.F.,
Turin, Italy) over 30 min through a separate i.v. access.
Blood samples were collected at 15, 30, 45, 60, and 90 min
after the bolus and the beginning of the infusion and cen-
trifuged at 10009g for 10 min at 4 C: serum was then
collected by aspiration and stored at -20 C until assayed
for GH. IGF-I, IGF-II, osteocalcin, and C-terminal
telopeptide of type I collagen (CTx) values were measured
on blood samples collected at baseline. Cross-linked N-
telopeptides of type I collagen (NTx) were assayed on 24-h
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urinary collections, and values were corrected for urinary
creatinine. In particular, values of both somatomedins were
measured in 139 patients, while biochemical markers of
bone turnover were available from 95 subjects (49 men and
46 women).
Biochemical assays
GH serum concentrations were measured by chemilumi-
nescent assay (CLIA, Nichols Institute Diagnostics, San
Juan Capistrano, CA, USA). Intra-assay coefficients of
variation for mean GH levels of 0.8, 5.9, and 17.1 lg/l
were 2.8, 3.7 and 5.4 %, respectively. Inter-assay coeffi-
cients of variation for mean GH levels of 0.1, 6.2 and
16.1 lg/l were 7.5, 6.2 and 8.7 %, respectively. The sen-
sitivity of the assay is 0.02 lg/l. The assay was calibrated
against the IS 98/574 recombinant standard. Severe GH
deficiency (GHD) was defined by a GH peak lower than
9 lg/l, while partial GHD was diagnosed with a peak
ranging from 9 to 16.5 lg/l; GH peaks greater than
16.5 lg/l were considered normal.
IGF-I serum concentrations were assayed by CLIA
(Nichols Institute Diagnostics, San Juan Capistrano, CA,
USA) after IGF-I separation from insulin-like growth fac-
tor binding proteins (IGFBPs) by sample acidification.
Intra-assay coefficients of variation for mean IGF-I levels
of 63, 208, and 766 lg/l were 4.8, 5.2, and 4.4 %,
respectively. Inter-assay coefficients of variation for mean
IGF-I levels of 62, 215, and 811 lg/l were 7.1, 5.7, and
7.4 %, respectively. Sensitivity is 6 lg/l. Data are expres-
sed as IGF-I standard deviation score (SDS) values, cal-
culated according to Brabant et al. [8]. IGF-I SDS values
lower than -1.88 (3rd percentile) were considered abnor-
mally low.
Serum IGF-II was determined by radioimmunoassay
(RIA, Mediagnost GmbH, Reutlingen, Germany) using
specific polyclonal antibodies with high affinity. Intra- and
inter-assay coefficients of variation were 5.4 and 7.9 %,
respectively. Cross-reactivity with IGF-I is below 0.05 %
and sensitivity is 0.1 lg/l. Values between 360 and 880 lg/
l (3rd and 97th percentile in a healthy population aged
20–40 years, respectively) were considered normal.
Serum osteocalcin was measured by electrochemilumi-
nescence immunoassay (ECLIA, Roche Diagnostics
GmbH, Mannheim, Germany). The sensitivity of the assay
is 0.5 lg/l, while intra- and inter-assay coefficients of
variation are 3 and 4 %, respectively. Reference range is
12.0–52.1 lg/l for men and 6.5–42.3 l/l for women.
Serum CTx was measured on the Elecsys 2010 auto-
mated analyzer (Roche Diagnostics GmbH, Mannheim,
Germany) using the b-Crosslaps/serum reagents. This
assay is specific for cross-linked b-isomerized type I col-
lagen C-telopeptide fragments and uses two monoclonal
antibodies [9]. The sensitivity of the assay is 70 ng/l. The
upper limit of normal range is 580 ng/l for men and
540 ng/l for premenopausal women.
Urinary NTx was determined by enzyme-linked
immunosorbent assay (ELISA, Wampole Laboratories,
Princeton, NJ, USA). The lower limit of detection is
20 nmol BCE, while intra- and inter-assay coefficients of
variation are 5 and 5 %, respectively. Reference range for
men and premenopausal women is 5–65 nmol BCE/mmol
creatinine.
Serum ferritin was measured by ECLIA (Roche Diag-
nostics). Intra- and inter-assay coefficients of variation
were 1.8 and 2.9 %, respectively. The sensitivity of the
assay is 0.5 lg/l. Reference range is 30–400 lg/l in males
and 13–150 lg/l in females.
Statistical analysis
Results are presented as mean ± standard error of the
mean (SEM). Normal distribution of data was assessed by
the Kolmogorov–Smirnov test. Student’s t test for unpaired
data was used for comparison between groups. Chi-squared
test was used for comparison of quantitative variables.
Linear regression analysis was used to evaluate associa-
tions between variables. Statistical analyses were per-
formed with a commercially available software package
(STATVIEW, Abacus Concepts, Berkeley, CA, USA). A
p value lower than 0.05 was considered statistically
significant.
Results
Short stature, classically defined as a height SDS below
-1.88 (third percentile), was present in 48 out of the 139
(34.5 %) patients studied and, in particular, in 35 out of the
106 (33 %) patients who underwent BMD measurement.
Femoral osteoporosis/Z score below the expected range
for age was documented in 65 of the 106 (61.3 %) patients
undergone hip DEXA, while lumbar osteoporosis/Z score
below the expected range for age was demonstrated in 60
of the 106 (56.6 %) patients submitted to L1–L4 DEXA. In
particular, the prevalence of femoral osteoporosis/Z score
below the expected range was comparable in men (34/55,
i.e., 61.8 %) and women (31/51, i.e., 60.7 %), and the same
held true for lumbar osteoporosis/Z score below the
expected range (33/55, i.e., 60 %, in men and 27/51, i.e.,
52.9 %, in women).
Height SDS was not correlated with lumbar Z score; the
correlation between height SDS and femoral Z score approa-
ched statistical significance (p = 0.07), without attaining it.
Mean femoral Z score was not significantly different between
short subjects and the remaining patients (-2.41 ± 0.79 vs.
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-1.9 ± 1.55, NS, respectively), and the same held true for
lumbar Z score (-2.31 ± 0.97 vs. -2.0 ± 1.25, NS,
respectively). Likewise, the prevalence of osteoporosis/
Z score below the expected range for age at both sites was
comparable in short subjects and the remaining patients (23/
35, i.e., 65.7 %, vs. 42/71, i.e., 59.1 %, respectively, at
femoral level and 19/35, i.e., 54.2 %, vs. 41/71, i.e., 57.7 %,
respectively, at lumbar level).
The mean GH peak in response to GHRH plus arginine
was 18.0 ± 11.98 lg/l. According to the established crite-
ria for the interpretation of this test [10], 19 of 68 (27.9 %)
adult thalassemic patients displayed severe GHD. In par-
ticular, the prevalence of GHD was similar in male (10/36,
i.e., 27.7 %) and female (9/32, i.e., 28.1 %) patients. IGF-I
SDS was below -1.88 in 120 out of 139 (86.3 %) patients:
the prevalence of IGF-I deficiency was significantly greater
in women than in men (63/67, i.e., 94.0 %, vs. 57/72, i.e.,
79.1 %, p\ 0.05, respectively). Serum concentrations of
IGF-II ranged in our series from 665 to 2247 lg/l, with a
mean value of 893.7 ± 254.01 lg/l: in particular, none of
the 139 patients in whom IGF-II was measured displayed
circulating levels of the growth factor below the reference
range, while the same parameter was above the upper limit
of the range in 16 out of 139 (11.5 %) subjects.
Mean serum osteocalcin was 18.8 ± 16.75 lg/l in male
patients and 13.8 ± 12.75 lg/l in female patients, exceeding
the upper limit of normal range only in 4 % (2/49) of men and
2.1 % (1/46) of women. Mean serum CTx was 767.5 ±
434.95 ng/l in male patients and 610.3 ± 566.02 ng/l in
female patients, exceeding the upper limit of normal range in
59.1 % (29/49) of men and 45.6 % (21/46) of women. Mean
urinary NTx was 76.9 ± 61.65 nmol BCE/mmol creatinine in
the whole group of patients, exceeding the upper limit of nor-
mal range in 49.4 % (47/95) of them.
GH peaks were positively correlated with femoral neck
(r = 0.273, p\ 0.05), but not lumbar, Z score (Fig. 1). No
correlations were found between GH peaks on the one hand
and osteocalcin, CTx and NTx on the other hand. On the
contrary, GH peaks were positively correlated with IGF-I
values (r = 0.31, p\ 0.01), which in their turn displayed a
positive correlation with osteocalcin (r = 0.58,
p\ 0.0001), CTx (r = 0.56, p\ 0.0001), and NTx
(r = 0.54, p\ 0.0001) as well (Fig. 2), and a negative
correlation with the age of patients (r = -0.53,
p\ 0.0001). No correlations emerged between IGF-I val-
ues and either femoral or lumbar Z scores. Likewise, no
correlations were found between IGF-II and any of the
following parameters: GH peaks, osteocalcin, CTx, NTx,
femoral Z score, and lumbar Z score. Like IGF-I, IGF-II
was negatively correlated with age (r = -0.19, p\ 0.05).
Interestingly, no correlations emerged between height
SDS or BMI values and any of the following parametres:
GH peaks, IGF-I SDS, and IGF-II.
Fig. 2 Correlations between IGF-I values and serum osteocalcin (a), serum CTx (b) and urinary NTx (c) in adult thalassemic patients
Fig. 1 Correlations between stimulated GH secretion and femoral
(a) and lumbar (b) Z scores in adult thalassemic patients
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Finally, mean serum ferritin was 1686.7 ± 462.73 lg/l,
and no correlations were found between ferritin levels and
Z score values at both skeletal sites.
The same pattern of correlations described in the whole
group of patients was also evident in the subset of ‘‘os-
teoporotic’’ subjects.
Discussion
The present study provides further insights into the rela-
tionships between GH and somatomedin axis and bone
mineralization and turnover in adult thalassemic patients.
The merging of original data with previous knowledge has
allowed us to propose new hypotheses for the interpretation
of this aspect of the complex pathophysiology of bone
disease in this clinical condition.
Our data confirm the high prevalence of both GHD and
bone demineralization in adults with thalassemia, but both
these epidemiological findings are matters of scientific
debate. By performing a single-challenge test, i.e.,
GHRH ? arginine, we have repeatedly reported a preva-
lence of severe GHD ranging from one-fifth to one-fourth
in our series of thalassemic patients [1, 11], and this fig-
ure is confirmed in the current group of subjects. The lit-
erature on this topic, however, is quite discordant with
papers describing both higher and lower prevalence. De
Sanctis et al. [12] found severe GHD in up to 55 % of their
patients after glucagon stimulation. On the contrary, with
the use of two provocative tests, Pincelli et al. [13] could
confirm the presence of severe GHD in only 8 % of
patients. The figure of 55 % of the former study is very
likely overestimated, since the period of observation after
glucagon injection, a test known to elicit physiologically
delayed GH responses, was too short. On the other hand,
the possibility that in this clinical condition the prevalence
of GHD is lower than generally appreciated with the use of
a single test is worth investigating, with the perspective of
avoiding inappropriate GH replacement.
The lack of correlations between height SDS values and
GH peaks/IGF-I SDS values is not surprising when consid-
ering the role commonly assigned to factors other than or
additional to somatotropin-somatomedin deficiency, such as
gonadotropin deficiency, hypoxia, bone marrow expansion,
and nutritional deficits, in the pathophysiology of growth
retardation in these patients [11]. Likewise, the lack of cor-
relation between BMI values and GH peaks is not unexpected
in our subjects, given the widely accepted hypothesis that
factors other than anthropometric parameters, such as iron
overload in the early phase of life or cell damage deriving from
hypoxia, contribute to GHD in thalassemia [11].
The real prevalence of osteoporosis in this clinical
condition is also debated, because different techniques for
measuring BMD yield discordant results. In particular,
values measured by traditional DEXA resulted lower when
compared with those determined by quantitative-computed
tomography (QCT) in these patients. Therefore, the
prevalence of bone demineralization in thalassemia appears
to be lower in studies performed with QCT. However, the
reliability of this technique in this clinical condition has
recently been challenged by a study demonstrating higher
BMD values, measured by QCT, in patients than in con-
trols [14].
Stature may influence BMD measurement: indeed, a
10-cm difference in height has been estimated to corre-
spond to a difference in T score of about 0.35 at the femoral
neck and 0.40 at the spine, and this may lead to an over-
diagnosis of osteoporosis in small subjects. However,
studies performed in both pediatric and adult populations
point to low height as a predictor of low BMD [15, 16].
Our findings, not supporting a major role of short stature as
a determinant of bone demineralization in thalassemia,
underline the peculiarity of this complication. Indeed,
several factors are thought to contribute to bone disease in
this clinical condition, including genetic susceptibility,
partial persistence of ineffective erythropoiesis, negative
effects of iron overload and/or chelation therapy on
osteoblast function [2–5]. The iron chelators desferriox-
amine, deferiprone, and deferasirox have also been shown
to decrease both tartrate-resistant acid phosphatase and
cathepsin K expression, as well as osteoclast activity [17].
In vivo, in the experience of Wong et al. [18], the decline in
femoral neck Z score was accelerated after transition from
desferrioxamine to deferasirox in a large group of young
thalassemic patients. As regards endocrine factors,
according to our previous experience [1], both delayed
replacement of hypogonadism and somatotropin-so-
matomedin deficiency may play a role. Indeed, in non-
thalassemic untreated GH deficient adults an increased
fracture rate is well established [19, 20].
To the best of our knowledge, the present study is the
first to address the issue of circulating IGF-II in tha-
lassemia. In contrast with serum IGF-I, which was abnor-
mally low in the vast majority of our patients, IGF-II was
normal in most of them, even exceeding the upper limit of
reference range in about one tenth of patients. Furthermore,
given the lack of correlation between GH peaks and IGF-II
values, the production of this growth factor appears to be
largely independent of GH secretion in thalassemia, as well
as reported in the normal population, where physical
activity and mechanical loading seem to be the chief reg-
ulators. On the contrary, the finding of a positive correla-
tion between GH peaks and IGF-I levels confirms that in
thalassemia the GH secretory status retains its influence on
IGF-I production. According to our previous experience
[11], another relevant factor influencing IGF-I production
Endocrine (2016) 53:551–557 555
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in thalassemia is represented by reduced liver protidosyn-
thetic activity.
IGF-II, traditionally considered as a growth factor
involved in growth of fetal tissues and cancer cells, is now
emerging as a potential regulator of metabolism and body
composition. Indeed, this growth factor has been shown to
stimulate glucose uptake and to exert antilipolytic activity
in cell cultures [21], as well as to stimulate preadipocyte
proliferation, skeletal myoblast differentiation, and myofi-
ber hypertrophy [22–24]. Furthermore, both IGFs promote
osteoblast proliferation, differentiation, and function [6]
and, when administered to humans and rodents, they
increase biochemical markers of osteoblast function [25,
26]. Most studies carried out in pre- and post-menopausal
women of different ethnic groups have failed to demon-
strate an association between circulating IGF-II and BMD
[27–30], but such a correlation has been recently described
in women after adjusting for age [7, 31] and in men [32]. In
particular, in the experience of Sittadjody et al. [7], cir-
culating IGF-II was positively correlated with calcaneal
BMD and serum osteocalcin in post-menopausal Indian
women, suggesting an influence of this growth factor on
bone density also in female gender.
As regards thalassemia, we failed to demonstrate a
correlation between serum IGF-II and femoral or lumbar
Z score in our current series. Furthermore, at variance with
what previously reported by ourselves in a smaller group of
patients [1], we also failed to find an association between
serum IGF-I and BMD. This lack of correlation militates
against a major role of circulating IGFs in the pathophys-
iology of bone demineralization in thalassemia. On the
contrary, given the positive correlations between serum
IGF-I and markers of bone resorption and formation, the
ability of the growth factor to promote bone turnover seems
to be preserved in these patients.
The positive correlation between GH stimulated release
and femoral, but not lumbar, Z score confirms our previous
observations [1] and points to GH secretory status as a
determinant of bone health in this clinical condition: the
discrepant finding at the two skeletal sites might be
accounted for by the well established greater negative
influence of GHD on cortical than on trabecular bone [33].
In conclusion, our study contributes to a better under-
standing of the involvement of the GH-somatomedin axis
in the pathophysiology of osteoporosis in this disease. In
particular, the contribution of somatotropin deficiency to
femoral demineralization is confirmed; however, this effect
appears to be likely mediated by locally produced rather
than circulating IGF-I. Along this line of interpretation, a
reduced bone content of IGF-I had been described in the
past by other investigators [34] in non-thalassemic post-
menopausal women. If, on the one hand, our data allow
new hypotheses for the interpretation of the puzzling issue
of bone disease in thalassemia, on the other hand, the
discrepancy between the rate of BMD lower than expected
and the frequency of clinical fractures remains to be elu-
cidated. Furthermore, our findings encourage studies on the
prevalence of morphometric fractures in these patients.
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